WAVEMAN · COMPANY

CDIO · Cardio Diagnostics Holdings, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

CDIO

Name: Cardio Diagnostics Holdings, Inc. (CDIO) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Cardio Diagnostics Holdings, Inc.

PHARMA & BIOTECH · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · CIK 0001870144

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

-57.5%

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

5 funds added or opened last quarter

below 96% of Pharma & Biotech

REVENUE

-57.5% year over year

below 85% of Pharma & Biotech

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

0.8% of shares outstanding short · 1.0 days to cover · settled 2026-07-31

below 74% of Pharma & Biotech

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -53.0%

-53.0%12M

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 5 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Cardio Diagnostics Holdings, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Philibert Robert

Chief Medical Officer

BUY

2024-09-06

26,615.0

$7.7K

Philibert Robert

Chief Medical Officer

BUY

2024-09-06

7,460.0

$2.1K

Dogan Meeshanthini

Chief Technology Officer

BUY

2024-09-06

68,965.0

$20.0K

Dogan Meeshanthini

Chief Executive Officer

BUY

2024-09-06

68,965.0

$20.0K

Dogan Timur

Chief Technology Officer

BUY

2024-09-06

68,965.0

$20.0K

13 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 8 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

RENAISSANCE TECHNOLOGIES LLC

49,200.0 sh

$107.7K

BlackRock, Inc.

34,708.0 sh

$76.0K

GEODE CAPITAL MANAGEMENT, LLC

26,233.0 sh

$57.4K

VANGUARD CAPITAL MANAGEMENT LLC

20,155.0 sh

$44.1K

CITADEL ADVISORS LLC

19,071.0 sh

$41.8K

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Fidelity Extended Market Index Fund

$108.5K POSITION · AS OF 2026-02-28

0.0%

VANGUARD EXTENDED MARKET INDEX FUND

$39.3K POSITION · AS OF 2026-03-31

0.0%

Fidelity Series Total Market Index Fund

$12.2K POSITION · AS OF 2026-02-28

0.0%

Fidelity Total Market Index Fund

$14.7K POSITION · AS OF 2026-02-28

0.0%

Fidelity Nasdaq Composite Index Fund

$2.6K POSITION · AS OF 2026-02-28

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$14.8K	$34.9K	$17.1K	$950
OPERATING INCOME	$-6.5M	$-8.4M	$-7.2M	$-4.5M
NET INCOME	$-6.5M	$-8.4M	$-8.4M	$-4.7M
EPS (DILUTED)	-3.71	-9.35	-0.66	-1.51
OPERATING CASH FLOW	$-5.7M	$-5.0M	$-5.7M	$-5.1M
CASH	$0	$0	$0	$0

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE